A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
← catalyst calendarNCT06809400 · readout ≤ 529 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
127estimated
Sites
14
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-18 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson Disease
Interventions
- Drug: LY4006896
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Part A
measured Baseline to Week 48
Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A
measured Baseline to Week 48
Number of Participants with One or More SAEs Part B
measured Baseline to Week 61
Number of Participants with One or More TEAEs Part B
measured Baseline to Week 61
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed